$ITCI
Intra-Cellular Therapies, Inc.

2016 Q2 Form 10-Q Financial Statement

#000119312516563851 Filed on April 28, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $228.4K $0.00 $3.315K
YoY Change 298.06% -100.0% -98.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.470M $5.060M $3.770M
YoY Change 62.16% 34.22% 97.38%
% of Gross Profit
Research & Development $25.30M $23.43M $18.63M
YoY Change 42.44% 25.77% 558.55%
% of Gross Profit
Depreciation & Amortization $50.00K $47.97K $15.24K
YoY Change 66.67% 214.74% 141.25%
% of Gross Profit
Operating Expenses $31.77M $28.50M $22.40M
YoY Change 46.09% 27.2% 691.86%
Operating Profit -$31.54M -$28.50M -$22.40M
YoY Change 45.42% 27.22% 389.69%
Interest Expense $710.0K $660.0K $110.0K
YoY Change 294.44% 500.0% 2082.11%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$30.83M -$27.84M -$22.29M
YoY Change 43.35% 24.91% 390.97%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.83M -$27.84M -$22.29M
YoY Change 43.34% 24.92% 390.54%
Net Earnings / Revenue -13497.54% -672302.38%
Basic Earnings Per Share
Diluted Earnings Per Share -$713.0K -$644.6K -$724.2K
COMMON SHARES
Basic Shares Outstanding 43.23M shares 43.21M shares 34.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $442.7M $456.1M $235.2M
YoY Change 117.01% 93.92% 61.54%
Cash & Equivalents $51.97M $37.24M $100.8M
Short-Term Investments $390.7M $418.8M $134.4M
Other Short-Term Assets $4.000M $6.800M $1.300M
YoY Change -53.49% 423.08% 116.67%
Inventory
Prepaid Expenses
Receivables $98.24K $0.00 $3.315K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $446.8M $462.9M $236.5M
YoY Change 110.15% 95.71% 61.57%
LONG-TERM ASSETS
Property, Plant & Equipment $718.7K $731.4K $559.7K
YoY Change -0.48% 30.68% 760.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $75.77K $71.88K $70.94K
YoY Change 6.8% 1.31% -64.61%
Total Long-Term Assets $794.4K $803.3K $630.7K
YoY Change 0.17% 27.38% 137.51%
TOTAL ASSETS
Total Short-Term Assets $446.8M $462.9M $236.5M
Total Long-Term Assets $794.4K $803.3K $630.7K
Total Assets $447.6M $463.7M $237.1M
YoY Change 109.74% 95.53% 61.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.890M $1.959M $4.574M
YoY Change -20.8% -57.17% 113.48%
Accrued Expenses $15.50M $7.000M $10.00M
YoY Change 252.27% -30.0% 455.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.38M $8.947M $14.59M
YoY Change 107.99% -38.69% 273.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.300M $2.000M $200.0K
YoY Change 360.0% 900.0%
Total Long-Term Liabilities $2.259M $1.971M $160.1K
YoY Change 351.8% 1130.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.38M $8.947M $14.59M
Total Long-Term Liabilities $2.259M $1.971M $160.1K
Total Liabilities $21.64M $10.92M $14.75M
YoY Change 119.95% -26.0% 278.28%
SHAREHOLDERS EQUITY
Retained Earnings -$251.7M -$220.9M -$110.5M
YoY Change 90.62% 99.82% 77.99%
Common Stock $677.6M $673.7M $333.0M
YoY Change 101.87% 102.34% 11394548.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $426.0M $452.7M $222.4M
YoY Change
Total Liabilities & Shareholders Equity $447.6M $463.7M $237.1M
YoY Change 109.74% 95.53% 61.71%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$30.83M -$27.84M -$22.29M
YoY Change 43.34% 24.92% 390.54%
Depreciation, Depletion And Amortization $50.00K $47.97K $15.24K
YoY Change 66.67% 214.74% 141.25%
Cash From Operating Activities -$13.50M -$19.65M -$15.71M
YoY Change -56.45% 25.08% 125.07%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $3.874K $520.4K
YoY Change -78.95% -99.26% 16579.36%
Acquisitions
YoY Change
Other Investing Activities $28.09M $9.570M -$66.18M
YoY Change 1612.8% -114.46%
Cash From Investing Activities $28.05M $9.570M -$66.70M
YoY Change 1847.92% -114.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $129.9M
YoY Change 11.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 160.0K 121.9M
YoY Change 11.76% -99.87% 5.58%
NET CHANGE
Cash From Operating Activities -13.50M -19.65M -15.71M
Cash From Investing Activities 28.05M 9.570M -66.70M
Cash From Financing Activities 190.0K 160.0K 121.9M
Net Change In Cash 14.74M -9.920M 39.48M
YoY Change -150.15% -125.13% -63.6%
FREE CASH FLOW
Cash From Operating Activities -$13.50M -$19.65M -$15.71M
Capital Expenditures -$40.00K $3.874K $520.4K
Free Cash Flow -$13.46M -$19.65M -$16.23M
YoY Change -56.31% 21.09% 132.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 itci Net Proceeds From Public Offering
NetProceedsFromPublicOffering
121800000
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43232652 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100802133
CY2015Q3 us-gaap Share Price
SharePrice
43.50
CY2015Q3 itci Net Proceeds From Public Offering
NetProceedsFromPublicOffering
327400000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
673679915
CY2016Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1745561
CY2016Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5241839
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
452744421
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3009660 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.61
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43232652 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.61
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1711965 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43232652 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.59
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3009660 shares
CY2016Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1970747
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
61000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1959272
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220890547
CY2016Q1 us-gaap Liabilities
Liabilities
10917419
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
463661840
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
4323
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2402833
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8946672
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49270
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71875
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
4140815
CY2016Q1 us-gaap Assets
Assets
463661840
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
110000
CY2016Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
437565000
CY2016Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
731429
CY2016Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
418827867
CY2016Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
8300000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
462858536
CY2016Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18700000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6790104
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37240565
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3134262
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
418877000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61325044
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2737657 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.72
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43155875 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43155875 shares
CY2015Q4 us-gaap Assets
Assets
484103528
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
592000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
459155000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30660
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
775522
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
4316
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2356838
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6263512
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-590410
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
71875
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1597105
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
669878103
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1207143
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3423464
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
476242911
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1632905
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193049098
CY2015Q4 us-gaap Liabilities
Liabilities
7860617
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
484103528
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
428041021
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
9200000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
483256131
CY2015Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
31100000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8025147
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47159303
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3132360
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
428632000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129900000
CY2015Q1 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
661481 shares
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7935000 shares
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
345200000
CY2015Q3 itci Share Issued During Period Shares Underwriters New Issues
ShareIssuedDuringPeriodSharesUnderwritersNewIssues
1035000 shares
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
19000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15709090
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30775287 shares
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
520396
CY2015Q1 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-66704655
CY2015Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4958644
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
121890834
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18632427
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
122083012
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1514091
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-22286824
CY2015Q1 us-gaap Revenues
Revenues
3315
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-21584
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
293214
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22400740
CY2015Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
71142903
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-151325
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-48288
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22216095
CY2015Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
70729
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
113916
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2099826
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39477089
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
22404055
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
160112
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101036
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3771628
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
45682
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2521586
CY2015Q1 us-gaap Depreciation
Depreciation
15240
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19650423
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018 pure
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001567514
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
53.63
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
Intra-Cellular Therapies, Inc.
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P3Y
CY2016Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.18
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
75134 shares
CY2016Q1 dei Trading Symbol
TradingSymbol
ITCI
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43193857 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
347137 shares
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3874
CY2016Q1 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-27841449
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1235043
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28497853
CY2016Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
32644315
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-182418
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-30660
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27300309
CY2016Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
541140
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
656404
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3592461
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9918738
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
28497853
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
373642
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9568002
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
42216191
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
163683
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23433620
CY2016Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2356793
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
163683
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5064233
CY2016Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
45675
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
326367
CY2016Q1 us-gaap Depreciation
Depreciation
47967
CY2016Q1 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
6000
CY2016Q1 itci Share Based Compensation Arrangement By Share Based Payment Award Canceled Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceledWeightedAverageRemainingContractualTerm
P0Y
CY2016Q1 itci Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents
MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents
Three months or less
CY2016Q1 itci Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P3Y4M24D
CY2016Q1 itci Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2
P6Y
CY2016Q1 itci Available For Sale Securities Maturity Period
AvailableForSaleSecuritiesMaturityPeriod
More than three months

Files In Submission

Name View Source Status
0001193125-16-563851-index-headers.html Edgar Link pending
0001193125-16-563851-index.html Edgar Link pending
0001193125-16-563851.txt Edgar Link pending
0001193125-16-563851-xbrl.zip Edgar Link pending
d183727d10q.htm Edgar Link pending
d183727dex101.htm Edgar Link pending
d183727dex311.htm Edgar Link pending
d183727dex312.htm Edgar Link pending
d183727dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itci-20160331.xml Edgar Link completed
itci-20160331.xsd Edgar Link pending
itci-20160331_cal.xml Edgar Link unprocessable
itci-20160331_def.xml Edgar Link unprocessable
itci-20160331_lab.xml Edgar Link unprocessable
itci-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending